Lv3
310 积分 2024-06-26 加入
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
6天前
已完结
Hepatocellular Carcinoma
12天前
已完结
UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan‐induced toxicity: A meta‐analysis
1个月前
已完结
肝细胞癌术后辅助治疗专家共识（2026版）
2个月前
已完结
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)
3个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
5个月前
已完结
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
5个月前
已完结
Temporospatial Recurrence Patterns and Predictive Factors for Recurrences in 984 Patients With Adult Soft Tissue Sarcomas
5个月前
已完结
Local recurrence of soft tissue sarcoma a risk factor for late metastases: 379 patients followed for 0.5-20 years
5个月前
已完结
Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network
5个月前
已完结
皖公网安备34019202002308
